58. 肥大型心筋症 ［臨床試験数：55，薬物数：70（DrugBank：31），標的遺伝子数：31，標的パスウェイ数：137］
Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04133532 | November 1, 2019 | 4 November 2019 | Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy | Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy | Drug: Metoprolol | University Hospital, Motol | Not recruiting | 18 Years | 75 Years | All | 50 | Phase 4 | ||
| 2 | NCT04129905 | October 21, 2019 | 28 October 2019 | Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies | Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies | Hypertrophic Cardiomyopathy;Endothelial Dysfunction | Biological: BNP blood sample test;Diagnostic Test: Electrocardiogram;Diagnostic Test: Holter ECG;Diagnostic Test: Echocardiography;Diagnostic Test: Air venous plethysmography;Diagnostic Test: Upper member arterial Doppler echography with analysis of FMD;Biological: Endothelial function biomarkers | University Hospital, Bordeaux | Fédération Française de Cardiologie;Fondation Bordeaux Université;Amicus Therapeutics | Not recruiting | 18 Years | N/A | All | 40 | N/A | France |
| 3 | NCT03832660 | May 3, 2019 | 30 September 2019 | Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy | Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy | Behavioral: Lifestyle;Drug: Sacubitril/Valsartan | Newcastle University | Azienda Ospedaliero-Universitaria Careggi;University Hospital Regensburg;Institute for Cardiovascular Diseases of Vojvodina;University of Belgrade | Recruiting | 18 Years | 70 Years | All | 240 | Phase 2 | Germany;Italy;Serbia;United Kingdom |
| 4 | EUCTR2018-000029-29-NL | 11/12/2018 | 28 February 2019 | Extra energy for hearts with a genetic defect: ENERGY trial | Extra energy for hearts with a genetic defect: ENERGY trial - ENERGY | Hypertrophic cardiomyopathy;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Vastarel Product Name: Vastarel Pharmaceutical Form: Capsule, soft Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | VU University Medical Center | Authorised | Female: yes Male: yes | 40 | Phase 2 | Netherlands | |||
| 5 | EUCTR2017-002530-23-NL | 10/12/2018 | 28 February 2019 | A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscle | A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - EXPLORER-HCM | Hypertrophic Cardiomyopathy MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN | MyoKardia, Inc. | Authorised | Female: yes Male: yes | 220 | Phase 3 | United States;Portugal;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Denmark;Netherlands;Germany | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03767855 | December 4, 2018 | 14 October 2019 | A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects | A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multi-Part, Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects | Symptomatic Obstructive Hypertrophic Cardiomyopathy;Healthy Subjects | Drug: CK-3773274;Drug: Placebo | Cytokinetics | Recruiting | 18 Years | 55 Years | All | 108 | Phase 1 | United States | |
| 7 | ChiCTR-IIR-17013661 | 2018-10-10 | 15 October 2018 | Effect of beta-blockers combined with angiotensin II receptor blockers in regression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy: A multicenter randomized, controlled clinical trial | Effect of beta-blockers combined with angiotensin II receptor blockers in regression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy: A multicenter randomized, controlled clinical trial | Hypertrophic cardiomyopathy | Experimental group:Metoprolol Succinate Sustained-release Tablets combined with candesartan treatment;Control group:Metoprolol Succinate Sustained-release Tablets monotherapy; | The First Affiliated Hospital, Sun Yat-sen University | Recruiting | 18 | 65 | Both | Experimental group:130;Control group:130; | Phase 4 study | China | |
| 8 | NCT03723655 | October 5, 2018 | 11 November 2019 | A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM | A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE) | Hypertrophic Cardiomyopathy;Obstructive Hypertrophic Cardiomyopathy;Non-obstructive Hypertrophic Cardiomyopathy | Drug: mavacamten | MyoKardia, Inc. | Recruiting | 18 Years | N/A | All | 280 | Phase 2/Phase 3 | United States;Czechia;France;Germany;Italy;Poland;Portugal;Spain | |
| 9 | EUCTR2017-002530-23-DE | 04/10/2018 | 15 October 2018 | A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscle | A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - EXPLORER-HCM | Hypertrophic Cardiomyopathy MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | MyoKardia, Inc. | Authorised | Female: yes Male: yes | 220 | Phase 3 | United States;Portugal;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Denmark;Germany;Netherlands | |||
| 10 | EUCTR2017-002530-23-ES | 19/09/2018 | 1 October 2018 | A study to evaluate the safety and benefit of Mavacamten (MYK-461) in adults with an inherited heart disease causing thickening of the heart muscle | A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - EXPLORER-HCM | Hypertrophic Cardiomyopathy MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | MyoKardia, Inc. | Authorised | Female: yes Male: yes | 220 | Phase 3 | United States;Portugal;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Denmark;Germany;Netherlands | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2017-002530-23-PT | 17/09/2018 | 30 April 2019 | A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscle | A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - EXPLORER-HCM | Hypertrophic Cardiomyopathy MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Mavacamten Product Code: MYK-461 Pharmaceutical Form: Capsule INN or Proposed INN: NA CAS Number: NA Current Sponsor code: MYK-461 Other descriptive name: MAVACAMTEN | MyoKardia, Inc. | Authorised | Female: yes Male: yes | 220 | Phase 3 | Portugal;United States;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Denmark;Germany;Netherlands | |||
| 12 | NCT03607669 | June 1, 2018 | 20 August 2018 | Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium | Manganese-Enhanced Magnetic Resonance Imaging: Applications in Cardiomyopathy | Ischemic Cardiomyopathy;Dilated Cardiomyopathy;Hypertrophic Cardiomyopathy | Other: Mangafodipir trisodium | University of Edinburgh | Recruiting | 18 Years | 65 Years | All | 90 | Phase 2/Phase 3 | United Kingdom | |
| 13 | NCT03470545 | May 29, 2018 | 11 November 2019 | Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy | A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic Cardiomyopathy | Drug: mavacamten;Drug: Placebo | MyoKardia, Inc. | Not recruiting | 18 Years | N/A | All | 220 | Phase 3 | United States;Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom | |
| 14 | NCT02948998 | May 14, 2018 | 11 June 2018 | Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy | Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial | Hypertrophic Cardiomyopathy;Fibrosis | Drug: Spironolactone | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Ruijin Hospital;RenJi Hospital;Shanghai Jiao Tong University Affiliated Sixth People’s Hospital | Not recruiting | 18 Years | 75 Years | All | 260 | Phase 4 | China |
| 15 | NCT03057002 | May 1, 2018 | 21 January 2019 | UTSW HP [13-C] Pyruvate Injection in HCM | Detection of Regional Myocardial Metabolic Changes in Patients With Hypertrophic Cardiomyopathy Using Hyperpolarized Carbon 13 Magnetic Resonance Spectroscopic Imaging (MRSI) | Cardiomyopathy, Hypertrophic | Drug: Hyperpolarized 13C-Pyruvate | University of Texas Southwestern Medical Center | Recruiting | 18 Years | 60 Years | All | 10 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT03532802 | May 1, 2018 | 11 June 2018 | The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy. | The Effect of Metoprolol on Myocardial Function, Perfusion, Hemodynamics and Heart Failure Symptoms in Patients With Hypertrophic Obstructive Cardiomyopathy. | Hypertrophic Cardiomyopathy | Drug: Metoprolol Succinate;Drug: Placebo oral capsule | Steen Hvitfeldt Poulsen | Recruiting | 18 Years | N/A | All | 32 | Phase 2 | Denmark | |
| 17 | NCT03496168 | April 26, 2018 | 18 March 2019 | Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER | An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER) | Hypertrophic Cardiomyopathy | Drug: mavacamten | MyoKardia, Inc. | Not recruiting | 18 Years | N/A | All | 12 | Phase 2 | United States | |
| 18 | NCT03442764 | March 30, 2018 | 20 May 2019 | A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction | Non-obstructive Hypertrophic Cardiomyopathy | Drug: mavacamten;Drug: Placebo | MyoKardia, Inc. | Not recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States | |
| 19 | NCT03251287 | November 2017 | 16 December 2017 | Nitrite in Hypertrophic Cardiomyopathy (HCM) Study | Mechanistic Study of the Effect of Inorganic Sodium Nitrate on Cardiac and Skeletal Muscle Metabolic Efficiency in Patients With Hypertrophic Cardiomyopathy | Cardiomyopathy, Hypertrophic | Drug: Sodium Nitrate;Drug: Placebo;Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy;Diagnostic Test: Exercise Stress Transthoracic Echocardiogram | University of East Anglia | Norfolk and Norwich University Hospitals NHS Foundation Trust;British Medical Research Council | Recruiting | 18 Years | 80 Years | All | 18 | Phase 1 | United Kingdom |
| 20 | NCT03249272 | September 5, 2017 | 19 November 2018 | Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve | Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve | Hypertrophic Cardiomyopathy;Non-ischemic Dilated Cardiomyopathy;Microvascular Ischaemia of Myocardium | Drug: Regadenoson;Drug: Adenosine | Duke University | Recruiting | 18 Years | N/A | All | 75 | Phase 4 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT03259113 | August 16, 2017 | 16 December 2017 | Insertable Cardiac Monitors in Hypertrophic Cardiomyopathy | EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic CardioMyopathy | Hypertrophic Cardiomyopathy | Device: Insertable cardiac monitor | Region Gävleborg | St. Jude Medical;Norrlands University Hospital | Recruiting | 18 Years | 65 Years | All | 30 | N/A | Sweden |
| 22 | NCT03953989 | October 2016 | 27 May 2019 | Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy | A Pilot Study Assessing the Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy | HCM - Hypertrophic Non-Obstructive Cardiomyopathy | Drug: Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die | IRCCS San Raffaele | Menarini International Operations Luxembourg SA | Recruiting | 18 Years | 80 Years | All | 26 | Phase 2 | Italy |
| 23 | NCT02862600 | August 1, 2016 | 16 December 2017 | Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure | A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function | Cardiomyopathy, Hypertrophic;Cardiomyopathy, Hypertrophic, Familial | Drug: Perhexiline;Device: Use of bioanalytical assay to monitor plasma levels of perhexiline | Heart Metabolics Limited | Not recruiting | 18 Years | N/A | All | 35 | Phase 2 | United States | |
| 24 | NCT02842242 | August 2016 | 29 April 2019 | A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction | A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction | Cardiomyopathy, Hypertrophic Obstructive;Left Ventricular Outflow Tract Obstruction | Drug: MYK-461 | MyoKardia, Inc. | Not recruiting | 18 Years | 70 Years | All | 21 | Phase 2 | United States | |
| 25 | EUCTR2015-002283-16-DK | 08/03/2016 | 8 August 2016 | An international study of the effect of Valsartan in hypertrophic cardiomyopathy. | Phase II randomized, placebo-controlled, double blind clinical trial of valsartan for attenuating disease evolution in early sarcomeric HCM - VANISH | Hypertrophic cardiomyopathy MedDRA version: 19.0 Level: LLT Classification code 10020204 Term: HOCM Hypertrophic obstructive cardiomyopathy System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Diovan 40 mg Pharmaceutical Form: Coated tablet INN or Proposed INN: VALSARTAN CAS Number: 137862-53-4 Current Sponsor code: Diovan Other descriptive name: Diovan Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Trade Name: Diovan 80 mg Pharmaceutical Form: Coated tablet INN or Proposed INN: VALSARTAN CAS Number: 137862-53-4 Current Sponsor code: Diovan Other descriptive name: Diovan Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 80- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Trade Name: Diovan 160 mg Pharmaceutical Form: Coated tablet INN or Proposed INN: VALSARTAN CAS Number: 137862-53-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | National Heart, Lung, and Blood Institute / National Institutes of Health | Authorised | Female: yes Male: yes | 150 | Phase 2 | Denmark | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT02560467 | December 1, 2015 | 17 June 2019 | Perfusion Imaging With Myocardial Contrast Echocardiography in HCM | Hypertrophic Cardiomyopathy | Drug: Echo and myocardial contrast echocardiography perfusion imaging | Oregon Health and Science University | Not recruiting | 19 Years | 80 Years | All | 10 | N/A | United States | ||
| 27 | EUCTR2015-003521-34-FR | 09/10/2015 | 7 December 2015 | Hypertrophic CARdiomyopathy symptom release by alpha stimulant MIDOdrine | Hypertrophic CARdiomyopathy symptom release by alpha stimulant MIDOdrine - Light-CARMIDO | Hypertrophic cardiomyopathy;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Gutron 2,5mg Pharmaceutical Form: Capsule INN or Proposed INN: MIDODRINE HYDROCHLORIDE CAS Number: 3092-17-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Gutron 5mg Pharmaceutical Form: Capsule INN or Proposed INN: MIDODRINE HYDROCHLORIDE CAS Number: 3092-17-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | CHU de Bordeaux | Authorised | Female: yes Male: yes | France | |||||
| 28 | NCT02590809 | October 7, 2015 | 16 December 2017 | Hypertrophic Cardiomyopathy Symptom Release by BX1514M | Hypertrophic Cardiomyopathy | Drug: Treatment BX1514M;Drug: Placebo;Other: Walk distance test;Other: Exercise echocardiography | University Hospital, Bordeaux | Not recruiting | 18 Years | 80 Years | All | 38 | Phase 2 | France | ||
| 29 | NCT02431221 | July 22, 2015 | 16 December 2017 | Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure | A Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure | Hypertrophic Cardiomyopathy | Drug: Perhexiline;Drug: Placebo | Heart Metabolics Limited | Not recruiting | 18 Years | N/A | All | 0 | Phase 3 | ||
| 30 | NCT02559726 | June 2015 | 4 July 2016 | Hyper-synchronicity in Hypertrophic Cardiomyopathy (HCM) : Description, Mechanism and Origin With a Multi-imaging Approach to Predict Dual Chamber Pacing Response | Identification and Quantification of a Mechanical Hyper-synchronicity State in Hypertrophic Cardiomyopathy (HCM) With Left Outflow-tract Obstruction and Description of Its Electrical and Electro-mechanical Characteristics Thanks to an Innovative Multi-imaging Approach to Predict a Positive Response to Dual Chamber Pacing. The Hsync Study. | Hypertrophic Cardiomyopathy;Mechanical Hyper-synchronicity | Procedure: Echocardiography (TEE);Device: Magnetic resonance imaging (MRI) with gadolinium enhancement;Device: Magnetic resonance imaging (MRI) without gadolinium enhancement;Procedure: 3D electrocardiographic mapping (ECM) | University Hospital, Bordeaux | Recruiting | 18 Years | N/A | Both | 60 | N/A | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2013-004429-97-GB | 24/03/2015 | 3 April 2017 | A clinical trial with GS-6615 for treatment of Symptomatic Hypertrophic Cardiomyopathy | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy | Subjects with symptoms (NYHA Class = II dyspnea or CCS Class = II angina) due to hypertrophic cardiomyopathy (defined by standard criteria as a maximal LV wall thickness of = 15 mm in the absence of other causative loading abnormalities capable of producing the magnitude of hypertrophy observed) MedDRA version: 19.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: GS-6615 3 mg White Product Code: GS-6615 3 mg White Pharmaceutical Form: Film-coated tablet INN or Proposed INN: No INN or proposed INN available CAS Number: 1443211-72-0 Current Sponsor code: GS-6615 Other descriptive name: CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: GS-6615 6 mg White Product Code: GS-6615 6 mg White Pharmaceutical Form: Film-coated tablet INN or Proposed INN: No INN or proposed INN available CAS Number: 1443211-72-0 Current Sponsor code: GS-6615 Other descriptive name: CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: GS-6615 3 mg Pink Product Code: GS-6615 3 mg Pink Pharmaceutical Form: Film-coated tablet INN or Proposed INN: No INN or proposed INN available CAS Number: 1443211-72-0 Current Sponsor code: GS-6615 Other descriptive name: CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- | Gilead Sciences, Inc. | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | France;United States;Australia;Israel;Netherlands;Germany;Italy;United Kingdom | |||
| 32 | NCT02329184 | December 2014 | 26 September 2016 | Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461 | Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Patient Volunteers With Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy | Drug: MYK-461 | MyoKardia, Inc. | Not recruiting | 18 Years | 65 Years | Both | 15 | Phase 1 | United States | |
| 33 | EUCTR2014-001577-13-GB | 15/07/2014 | 28 February 2019 | Trientine in Hypertrophic Cardiomyopathy | Copper Chelation in Hypertrophic Cardiomyopathy: Open-label pilot study of Trientine in patients with hypertrophic cardiomyopathy - Copper (II) Chelation therapy in the treatment of HCM | Hypertrophic Cardiomyopathy MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Trientine dihydrochloride Product Name: Trientine dihydrochloride Pharmaceutical Form: Capsule, hard INN or Proposed INN: Trientine Dihydrochloride CAS Number: 38260-01-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | Manchester University NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | 20 | Phase 4 | United Kingdom | |||
| 34 | NCT01912534 | April 2014 | 29 April 2019 | Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM | Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM | Hypertrophic Cardiomyopathy | Drug: Valsartan;Drug: Placebo | New England Research Institutes | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 8 Years | 45 Years | All | 211 | Phase 2 | United States;Canada |
| 35 | NCT01904396 | August 2013 | 19 February 2015 | Identification of Carnitine-Responsive Cardiomyopathy | Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness. | Carnitine Deficiency | Drug: Carnitine | University Health Network, Toronto | The Physicians' Services Incorporated Foundation | Not recruiting | 18 Years | N/A | Both | 30 | Phase 4 | Canada |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT01721967 | November 2012 | 16 December 2017 | Ranolazine for the Treatment of Chest Pain in HCM Patients | Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation | Hypertrophic Cardiomyopathy | Drug: Ranolazine | Duke University | Gilead Sciences | Not recruiting | 18 Years | N/A | All | 14 | Phase 4 | United States |
| 37 | NCT01696370 | April 2012 | 19 February 2015 | Trimetazidine Therapy in Hypertrophic Cardiomyopathy | A Phase 2b Randomised, Double Blind, Placebo-controlled Trial of Trimetazidine Therapy in Patients With Non-obstructive Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy | Drug: Trimetazidine;Other: Placebo capsule | University College, London | British Heart Foundation | Recruiting | 18 Years | N/A | Both | 90 | Phase 2 | United Kingdom |
| 38 | EUCTR2011-003392-10-GB | 23/01/2012 | 19 March 2012 | A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that ends up in the blood, and the safety and tolerability of study drug in Noonan syndrome patients. | An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy. | Noonan syndrome hypertrophic cardiomyopathy MedDRA version: 14.1 Level: PT Classification code 10029748 Term: Noonan syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 14.1 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Code: MEK162 Pharmaceutical Form: Film-coated tablet CAS Number: 606143-89-9 Current Sponsor code: MEK162 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- | Novartis Pharma Services AG | Authorised | Female: yes Male: yes | 22 | United Kingdom;United States | ||||
| 39 | EUCTR2011-004507-20-ES | 19/01/2012 | 16 February 2015 | SHMC | RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS | symptomatic hypertrophic cardiomyopathy (SHCM) MedDRA version: 14.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Ranexa Product Code: Ranolazine 500 mg PR tablets Pharmaceutical Form: Film-coated tablet INN or Proposed INN: RANOLAZINE CAS Number: 95635-55-5 Current Sponsor code: Ranolazine PR Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Ranexa Product Name: Ranolazine 750 mg PR tablets Pharmaceutical Form: Film-coated tablet INN or Proposed INN: RANOLAZINE CAS Number: 95635-55-5 Current Sponsor code: Ranolazine PR Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 750- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Ranexa Product Name: Ranolazine 1000 mg PR tablets Pharmaceutical Form: Film-coated tablet INN or Proposed INN: RANOLAZINE CAS Number: 95635-55-5 Current Sponsor code: Ranolazine PR Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Menarini International Operations Luxembourg S.A. | Not Recruiting | Female: yes Male: yes | 100 | Spain;Germany;Italy | ||||
| 40 | NCT01537926 | January 2012 | 16 December 2017 | Hypertrophic Regression With N-Acetylcysteine in HCM | Pilot Feasibility Study With N-acetylcystein (NAC) in Patients With HCM Caused by Sarcomere Proteins Mutations | Hypertrophic Cardiomyopathy | Drug: N-acetylcysteine;Drug: Placebo | The University of Texas Health Science Center, Houston | National Institutes of Health (NIH) | Not recruiting | 18 Years | N/A | All | 42 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | EUCTR2011-001191-19-DK | 26/10/2011 | 7 September 2015 | Effects on the heart in patients with hypertophic cardiomyopathy when treated with losartan. | Cardiac effects of inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy. | Hypertrophic cardiomyopathy MedDRA version: 14.0 Level: LLT Classification code 10020876 Term: Hypertrophic obstructive cardiomyopathy System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Losartan Bluefish 50 mg Product Name: Losartan Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Hjertemedicinsk klinik B, 2142, Rigshospitalet | Not Recruiting | Female: yes Male: yes | Denmark | |||||
| 42 | EUCTR2011-000038-12-GB | 13/09/2011 | 4 August 2015 | Trimetazidine therapy in Hypertrophic Cardiomyopathy | A Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy. - Trimetazidine therapy in hypertrophic cardiomyopathy | Hypertrophic cardiomyopathy (non-obstructive) MedDRA version: 16.1 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Vastarel 20mg film coated tablets Product Name: Trimetazidine Dihydrochloride 20mg Product Code: not applicable Pharmaceutical Form: Tablet INN or Proposed INN: trimetazidine dihydrochloride CAS Number: 13171-25-0 Current Sponsor code: not applicable Other descriptive name: 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | University College London (UCL) | Not Recruiting | Female: yes Male: yes | Phase 2b | United Kingdom | ||||
| 43 | NCT01375335 | June 2011 | 19 February 2015 | The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve Replacement | The Effects of Dobutamine on Postoperative Systolic Deformation and Diastolic Function in Patients With Hypertrophic Cardiomyopathy Operated for Aortic Valve Stenosis | Heart Failure | Drug: Dobutamine | University of Aarhus | Not recruiting | 19 Years | 90 Years | Both | 10 | Phase 4 | Denmark | |
| 44 | NCT00821353 | January 2009 | 19 February 2015 | Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy | Sinus Rhythm Maintenance in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation - Randomized Comparison of Antiarrhythmic Therapy vs. Radiofrequency Catheter Ablation (SHAARC) | Atrial Fibrillation;Hypertrophic Cardiomyopathy | Procedure: RF catheter ablation;Drug: Antiarrhythmic drugs | Institute of Cardiology, Warsaw, Poland | Not recruiting | 18 Years | 70 Years | Both | 90 | Phase 3 | Poland | |
| 45 | NCT00879060 | November 2007 | 19 February 2015 | Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy | Clinical and Therapeutic Implications of Fibrosis in Hypertrophic | Myocardial Fibrosis;Hypertrophic Cardiomyopathy | Drug: spironolactone | Tufts Medical Center | Recruiting | 18 Years | 70 Years | Both | 95 | Phase 4 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT00317967 | April 2007 | 19 February 2015 | Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart | Statin Induced Regression of Cardiomyopathy Trial - SirCat | Hypertrophic Cardiomyopathy | Drug: Atorvastatin;Drug: Placebo | University of Calgary | Heart and Stroke Foundation of Canada | Not recruiting | 18 Years | N/A | Both | 22 | Phase 3 | Canada |
| 47 | NCT00430833 | March 2007 | 19 February 2015 | CHANCE - Candesartan in Hypertrophic Cardiomyopathy | Candesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter Study | Hypertrophic Cardiomyopathy | Drug: candesartan | Charles University, Czech Republic | AstraZeneca | Not recruiting | 18 Years | N/A | Both | Phase 2 | Czech Republic | |
| 48 | NCT01150461 | February 2007 | 19 October 2017 | Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy | Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy | Drug: losartan;Drug: placebo | Massachusetts General Hospital | Not recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States | |
| 49 | NCT00500552 | December 2006 | 19 February 2015 | Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy | Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study) | Hypertrophic Cardiomyopathy | Drug: Perhexiline/Placebo | University Hospital Birmingham | British Heart Foundation;University College London Hospitals;University of Oxford | Not recruiting | 18 Years | 80 Years | Both | 44 | Phase 2 | United Kingdom |
| 50 | NCT00319982 | January 2006 | 19 October 2017 | Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem | Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem | Hypertrophic Cardiomyopathy | Drug: Diltiazem;Drug: Placebo | Brigham and Women's Hospital | National Heart, Lung, and Blood Institute (NHLBI);Boston Children’s Hospital | Not recruiting | 5 Years | 39 Years | All | 39 | Phase 2/Phase 3 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | EUCTR2005-000755-15-GB | 25/10/2005 | 19 March 2012 | Perhexiline therapy in patients with Hypertrophic Cardiomyopathy | Perhexiline therapy in patients with Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy | Product Name: Pexsig Pharmaceutical Form: Tablet INN or Proposed INN: Perxexiline CAS Number: 6724-53-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | University Hospital of Birmingham Foundation Trust | Authorised | Female: yes Male: yes | 50 | United Kingdom | ||||
| 52 | NCT00035386 | April 2002 | 19 February 2015 | Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study | Trans-Right Ventricular Approach to Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Feasibility Study | Hypertrophic Cardiomyopathy | Procedure: trans-right ventricular alcohol septal ablation (TRVASA) | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | N/A | Both | 12 | Phase 2 | United States | |
| 53 | NCT00011076 | February 2001 | 19 February 2015 | Pirfenidone to Treat Hypertrophic Cardiomyopathy | Double-Blind Placebo-Controlled Study of Pirfenidone, A Novel Anti-Fibrotic Drug in Symptomatic Patients With Hypertrophic Cardiomyopathy (HCM) Associated With Left Ventricular Diastolic Function | Hypertrophic Cardiomyopathy | Drug: Pirfenidone | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | N/A | Both | 50 | Phase 2 | United States | |
| 54 | NCT00001965 | December 1999 | 19 February 2015 | Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM) | Double Blind Placebo Controlled Study of Cyclosporin A in Patients With Left Ventricular Hypertrophy Caused by Sarcomeric Gene Mutations | Cardiomyopathy, Hypertrophic;Heart Hypertrophy | Drug: Cyclosporine A | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | N/A | Both | 32 | Phase 2 | United States | |
| 55 | NCT00001534 | September 1996 | 19 February 2015 | Long Term Effects of Enalapril and Losartan on Genetic Heart Disease | Double-Blind, Placebo-Controlled Study of the Long Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced Left Ventricular Hypertrophy in Non-Obstructive HCM | Hypertrophic Cardiomyopathy;Left Ventricular Hypertrophy;Myocardial Ischemia | Drug: Losartan | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | N/A | Both | 112 | N/A | United States |